, by Original Article
Posted By: Gary Granai - July 30, 2008 9:38 am
German chemicals and pharmaceuticals company Bayer AG said Wednesday its cooperation partner Johnson & Johnson Pharmaceutical Research and Development has submitted the new drug application, or NDA, to the U.S. Food and Drug Administration, or FDA, for rivaroxaban (Xarelto), a novel anticoagulant taken as one tablet, once-daily. Complete Article Submitted By The Outlook
